Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair... see more

TSXV:RP - Post Discussion

View:
Post by RPINVESTOR1 on Oct 21, 2024 7:39pm

A FAIR DEAL

1. 75% on Gross Asset Sales.

2. 50% on Gross Royalties.

3. 2 minority shareholders on Board of Private Company.

4. All volunteer Replicel Board of Directors. Each Director must hold a minimum of 100,000 shares in Replicel. At least 2 new members not chosen by the current Board.  

5. No conversion of options to shares in Replicel. The option recipients have not been able to excercise these options because their efforts have not improved the fortunes of the Company or the share price. Converting these options to shares and increasing the total share count at the expense of the long-suffering small shareholders is abusive and unacceptable.

6. All further Replicel expenses to be paid by the Private Company.
Comment by RPINVESTOR1 on Oct 21, 2024 9:11pm
and............. 7. Maximum $5.00 USD payout (not the current $2.00 USD on offer).